Payment overview · 2025
General Payments
$531.51
25 reported records · 17 companies
Healthcare provider profile · identity verified
Aaron B Brown, MD
Allopathic & Osteopathic Physicians|Family Medicine · TWIN FALLS, ID · NPI 1326128612
Verified facts
What the public records show
CMS Open Payments records show Aaron B Brown, MD received $531.51 in general payments during 2025 across 25 reported records.
Novo Nordisk Inc accounted for 17.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 240 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $94.36 | 17.8% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $67.51 | 12.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.99 | 9.8% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $41.50 | 7.8% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $32.72 | 6.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.11 | 5.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.89 | 4.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.48 | 4.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.99 | 4.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.55 | 4.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $19.37 | 3.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.40 | 3.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.34 | 3.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.31 | 3.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.88 | 3.2% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $14.67 | 2.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.44 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $531.51 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $94.36 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $94.36 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $67.51 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $51.99 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.99 | 2 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $41.50 | 2 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $32.72 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.11 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.89 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.55 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 63 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
240 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 643 | 166 |
| Omeprazole | Omeprazole | 404 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 371 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 344 | 92 |
| Duloxetine Hcl | Duloxetine Hcl | 243 | 49 |
| Eliquis | Apixaban | 240 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 238 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 232 | 70 |
| Lisinopril | Lisinopril | 226 | 58 |
| Gabapentin | Gabapentin | 204 | 53 |
| Losartan Potassium | Losartan Potassium | 187 | 59 |
| Metformin Hcl Er | Metformin Hcl | 185 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 183 | 50 |
| Spironolactone | Spironolactone | 177 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 157 | 40 |
| Furosemide | Furosemide | 156 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 145 | 39 |
| Trazodone Hcl | Trazodone Hcl | 145 | 33 |
| Metformin Hcl | Metformin Hcl | 137 | 40 |
| Ropinirole Hcl | Ropinirole Hcl | 133 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 108 | 33 |
| Sertraline Hcl | Sertraline Hcl | 102 | 29 |
| Potassium Chloride | Potassium Chloride | 99 | 29 |
| Finasteride | Finasteride | 97 | 27 |
| Pregabalin | Pregabalin | 96 | 20 |
| Ozempic | Semaglutide | 93 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 88 | 19 |
| Glipizide Er | Glipizide | 87 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 87 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 21 |
| Tramadol Hcl | Tramadol Hcl | 76 | 31 |
| Mirtazapine | Mirtazapine | 75 | 24 |
| Alendronate Sodium | Alendronate Sodium | 71 | 25 |
| Estradiol | Estradiol | 71 | 19 |
| Montelukast Sodium | Montelukast Sodium | 71 | 17 |
| Prednisone | Prednisone | 71 | 28 |
| Buspirone Hcl | Buspirone Hcl | 70 | 15 |
| Morphine Sulfate Er | Morphine Sulfate | 70 | suppressed |
| Simvastatin | Simvastatin | 68 | 16 |
| Allopurinol | Allopurinol | 67 | 19 |
| Meloxicam | Meloxicam | 66 | 17 |
| Mounjaro | Tirzepatide | 63 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 20 |
| Famotidine | Famotidine | 59 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 16 |
| Linzess | Linaclotide | 57 | suppressed |
| Celecoxib | Celecoxib | 56 | 16 |
| Alprazolam | Alprazolam | 55 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 18 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 53 | suppressed |
| Telmisartan | Telmisartan | 52 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Bupropion Xl | Bupropion Hcl | 44 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Lorazepam | Lorazepam | 42 | 17 |
| Carvedilol | Carvedilol | 41 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 41 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Torsemide | Torsemide | 37 | suppressed |
| Topiramate | Topiramate | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 15 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 12 |
| Risperidone | Risperidone | 34 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 26 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | 12 |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | 15 |
| Lithium Carbonate | Lithium Carbonate | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Nystatin | Nystatin | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 22 | suppressed |
| Buprenorphine | Buprenorphine | 21 | suppressed |
| Cartia Xt | Diltiazem Hcl | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 17 |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Rivastigmine | Rivastigmine | 20 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 19 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 13 |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 14 |
| Primidone | Primidone | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $531.51 · 25 records | Novo Nordisk Inc | ABRYSVO, BEYFORTUS, Bimzelx, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ENFLONSIA, FREESTYLE LIBRE 3, GARDASIL 9, GVOKE HYPOPEN, INSPIRE, KRYSTEXXA, LEQVIO, M-M-R II, MOUNJARO, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, UBRELVY, YUPELRI, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error